Clinical Trial Update: Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating serplulimab plus bevacizumab and chemotherapy for EGFR-mutant metastatic non-squamous non-small cell lung cancer after EGFR-TKI failure…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Serplulimab (serplulimab)

Snippet

Sponsor: Henan Cancer Hospital | Conditions: Non-Squamous Non-Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN